Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Artelo Biosciences (Nasdaq: ARTL) has received FDA clearance for its Investigational New Drug (IND) application for ART26.12, a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. This clearance allows Artelo to initiate a Phase 1 single ascending dose study for chemotherapy-induced peripheral neuropathy (CIPN), a condition with no FDA-approved treatment. ART26.12 is being developed as a non-opioid approach to manage painful neuropathies. The company expects Phase 1 trial results in the first half of 2025. Artelo's FABP inhibitor platform has attracted interest from potential partners due to its preclinical efficacy, novel mechanism, and strong patent estate.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.